{"title":"人单克隆抗体:最新成果。","authors":"D R Burton, C F Barbas","doi":"10.1080/21548331.1994.11443111","DOIUrl":null,"url":null,"abstract":"<p><p>The latest developments include an anti-HIV antibody that has 1,000 times the affinity of natural antibody and that neutralizes primary clinical isolates, and an anti-RSV antibody that reduces viral titers in mice by 12,000-fold within 24 hours.</p>","PeriodicalId":77164,"journal":{"name":"Hospital practice (Office ed.)","volume":"29 11","pages":"111, 114-6, 119 passim"},"PeriodicalIF":0.0000,"publicationDate":"1994-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21548331.1994.11443111","citationCount":"10","resultStr":"{\"title\":\"Human monoclonal antibodies: recent achievements.\",\"authors\":\"D R Burton, C F Barbas\",\"doi\":\"10.1080/21548331.1994.11443111\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The latest developments include an anti-HIV antibody that has 1,000 times the affinity of natural antibody and that neutralizes primary clinical isolates, and an anti-RSV antibody that reduces viral titers in mice by 12,000-fold within 24 hours.</p>\",\"PeriodicalId\":77164,\"journal\":{\"name\":\"Hospital practice (Office ed.)\",\"volume\":\"29 11\",\"pages\":\"111, 114-6, 119 passim\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1994-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/21548331.1994.11443111\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hospital practice (Office ed.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21548331.1994.11443111\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital practice (Office ed.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21548331.1994.11443111","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The latest developments include an anti-HIV antibody that has 1,000 times the affinity of natural antibody and that neutralizes primary clinical isolates, and an anti-RSV antibody that reduces viral titers in mice by 12,000-fold within 24 hours.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
